| Literature DB >> 34291005 |
Anahita Shokri Jamnani1, Aziz Rezapour2, Najmeh Moradi3, Mostafa Langarizadeh4.
Abstract
Background: The Willingness to pay (WTP) for and acceptance of cervical cancer prevention (CCP) methods have an important role in the control of this type of cancer. Therefore, the aim of this study was to estimate the WTP and acceptance of CCP methods with the contingent valuation method (CVM).Entities:
Keywords: Acceptance; Cervical Cancer; Human Papillomavirus Vaccine; Preventive Measures
Year: 2021 PMID: 34291005 PMCID: PMC8285557 DOI: 10.47176/mjiri.35.81
Source DB: PubMed Journal: Med J Islam Repub Iran ISSN: 1016-1430
Fig. 1Characteristics of Included Studies
| Author, year country | Aim of study |
Study | Participants: N (response rate) | Data collection tool | Type of prevention methods | Administration | Type of questions | Informed by …. information | Type of information |
|
1. Wordsworth S, et al: 2001: Scotland( | Assess the value of the cervical smear test to women, | A Postal Survey |
Women aged 20-59: 595 ( | Questionnaire | Pap-smear | Mailed |
Payment card | General |
Time of cervical smear, method of carrying out screening, time between smears |
|
2. Choi HCW et al, 2013: Hong Kong( | Provide a more representative and updated assessment on the acceptability of female adoles- cent HPVvaccination | Survey |
Mothers with daughters | Random digit-dialing telephone interviewing | HPV vaccination | Telephone interviewing | Open ended | General |
HPVvaccineand |
|
3. Rajiah K et al, 2015: Malaysia( |
Evaluate the knowledge, attitude, practice and to find out |
Cross-Sectional |
University students |
Self-administered | HPV vaccination | Telephone interviewing | - | - | - |
|
4. Tarekegn AA, et al, 2019: Ethiopia( | Willingness to pay and associated factors for cervical cancer screening program | Cross-Sectional Study | Female health professionals in the College of Medicine and Health Sciences: 392 (92.7) | Questionnaire | Screening service | Face-to-face |
Double- | - | - |
|
5. Tarekegn AA and Yismaw AE, 2019: Ethiopia ( | Willingness to accept and pay, and associated factors for human papilloma virus vaccination | Cross-Sectional Study | Female health professionals in the College of Medicine and Health Sciences: 392 (92.7) | Questionnaire | HPV vaccination | Face-to-face |
Double- | - | - |
|
6. Philips Z,et al, 2003: UK ( |
Delineate | Cross-Sectional Study |
female students at | Questionnaire | HPV vaccination | Mailed |
payment card | - | - |
|
7. Hoque ME et al, 2013: South Africa( |
Assess the awareness of CC and its risk | Cross-Sectional Study | undergraduate female students: 440 (97.7) | Questionnaire | HPV vaccination | Face-to-face | - | - | - |
|
8. Maharajan MK et al, 2015: Malaysia ( |
To assess the knowledge and determine variation | Cross-Sectional Study | Ethnically Diverse Medical Students: 302 (99) | Questionnaires | HPV vaccination | Face-to-face | - | - | - |
|
9. Kruiroongroj S et al, 2014: Thailand( |
Examine the level of knowledge, attitude, acceptance, and | Cross-Sectional Study | Female parents of girls aged 12-15 years: 861 (71.7) | Questionnaires | HPV vaccination | Face-to-face |
Payment card | - | - |
|
10. Songthap A et al, 2012: Thailand( |
Assess the knowledge and attitudes | Cross-Sectional Study |
Students: 644(80.5) | Questionnaires | HPV vaccination | Face-to-face | Closed-ended | - | - |
|
11. Alder S et al, 2015: Argentina ( |
explore | cross-sectional study | mothers of girls aged 9-15 year: 180 (85.3) | questionnaires | HPV vaccination | face-to-face | - | General | natural history of HPV and cervical cancer |
|
12. Dinh Thu H et al, 2018: Vietnam ( | Identifying mothers’ WTP for HPV vaccine for daughters, and the associated factors | Cross-Sectional Study | married women 15--49 years old: 606(96) | Questionnaires | HPV vaccination | Face-to-face | open ended | - | - |
|
13. Umeh IB et al, 2016: Nigeria ( | Assessed Nigerian mothers’ WTP for HPV vaccine. | Cross-Sectional Study | Mothers has girls aged 9–12: 438 (88) | Questionnaires | HPV vaccination | Face-to-face | open ended-payment card technique | - | - |
|
14. Philips Z et al, 2006: UK ( |
Experiment to test the construct validity of contingent valuation, by eliciting women’s | Randomised Experiment |
women eligible | Questionnaires | Screening service | Face-to-face |
payment | General and detailed |
Risk factors, incidence, screening efficacy, HPV testing as triage for low-grade |
|
15. Yan Yuen WW et al, 2018: Hong Kong ( |
Assessing the feasibility of delivering the HPV | Cross-Sectional Study |
girls aged 9 to 14: 1147 (89.9) | Questionnaires | HPV vaccination | Face-to-face | - | - | - |
|
16. Liao CH et al, 2009: Taiwan ( |
Apply the CVM to | Cross-Sectional Study |
women aged 20–55 years with at | Questionnaires | HPV vaccination | Face-to-face |
double-bounded | General | - |
|
17. Raab SS et al, 2002:USA ( |
WTP for New Papanicolaou Test | cross-sectional study |
female patients who attended | questionnaires | (liquid-based) Papanicolaou (Pap) test | face-to-face |
payment card | detailed |
conventional Pap smear screening, the, impact of Pap |
|
18. Dahlström LA et al, 2010: Sweden ( |
Investigated correlates of attitudes to | Population-Based Survey |
Parents of children aged 12–15 years: | Questionnaires | HPV vaccination |
Online | - | - | - |
|
19. Oh JK et al, 2010: Korea ( |
Awareness and acceptance of HPV infection | Population-Based Survey | Male (496) and female (504) adults: 1000 (27.3) | Questionnaires | HPV vaccination | Face-to-face |
Closed-ended questionnaire including some multiple | - | - |
|
20. Rajiah K et al, 2017: Malaysia ( |
Determine the influence of dental students’ knowledge and attitude | Cross-Sectional Study |
Final | Questionnaires | HPV vaccination | Face-to-face | Opened-ended questions | - | - |
|
21. Tran BX et al, 2018: Vietnam ( | investigate barriers related to knowledge–attitude–practice (KAP) about the HPV vaccine and WTP for the vaccine | cross-sectional study | vaccination service users: 492 | questionnaires | HPV vaccination | face-to-face | Double-bounded dichotomous-choice questions with open-ended questions | - | - |
|
22. Touch S and Oh JK, 2018: Cambodia ( |
examine the cervical cancer knowledge, attitudes, and practices as well as | cross-sectional study | women aged 20–69 years: 440(98.8) | questionnaires | HPV vaccination | face-to-face interview survey |
close-ended, | - | - |
|
23. Opoku CA et al, 2016: Ghana ( | assessed the perception of risk of CC and existence of risk factors for CC | cross-sectional study |
women had to be between the ages of |
semistructured | screening service | face-to-face interview survey | - | - | - |
|
24. Lin Y et al, 2020:China ( | investigate acceptance and willingness to pay for HPV vaccination among adult women in China | cross-sectional study | mothers aged 27–45 years of primary school pupils: 2339 (62) | questionnaires | HPV vaccines | online | open ended single bounded dichotomous-choice-open ended | - | - |
|
25. You D et al, 2020: China ( | determine HPV vaccine uptake and willingness to receive HPV vaccination | cross-sectional survey | female college students: 4220 | questionnaires | HPV vaccines | online | - | - | - |
|
26.Lin W et al, 2020: China( | Valuate the differences on awareness and attitude towards HPV and its vaccine between local and migrant residents who participated in CC screening | Cross-Sectional Survey | women aged from 21 to 60 years: 9855 (93.8) | Questionnaires | HPV vaccines | Face-to-face | Open ended | - | - |
|
27.Kristina S et al, 2020: Indonesia( | Examine the perception of seriousness and knowledge of CC risk and to evaluate the WTP for CC screening | Community based cross-sectional survey | women who visited clinics or pharmacies: 675 | Questionnaires | Screening service | Face-to-face | Bid contingent valuation method | - | - |
|
28.Weng Q et al, 2020: Tanzania ( | Describe women’s awareness of CC and to explore the attitudes toward, acceptability of and barriers to CC | Cross-sectional | women aged 14–65 years old: 1483 (98.8) | Questionnaires | Screening service | Face-to-face | Closed-response questions | - | - |
Results of Included Studies
| Author, year country | Demographic characteristics of participants | % of acceptance of test | % of Positive WTP | WTP (US$) M±SD OR median (CR) |
WTP as a | Other results |
| Main reason for no WTP (%) | |
| Significant positive | non-significant | ||||||||
|
|
Mean age: 38 | - | 89.3 | 80.8±51.5 | 0.49 | Zero value=10.7% of participants |
|
|
|
|
| 83% of mother has more than 35 years |
Schoolgirls: 27.1 |
Schoolgirls:54.8 |
Schoolgirls:38 (13–128) |
Schoolgirls:0.12 |
Perceived minimum age appropriate for |
Mothers: |
Mothers: | |
|
|
mean age: 22.2 | 83.8 | 86 | 108.66 | 0.97 |
- Almost all the students wanted the vaccine to be cost free | - | - | Cost |
|
|
mean age: 28 years | - | 83.4 | 7.12±4.83 | 0.91 | 34.6% of participants were WTP more than US$11 |
|
|
|
|
|
mean age: 28 years | - | 85.9 | 8.46±4.83 | 1.09 | 36.6% of participants were WTP more than US$11 |
|
|
|
|
|
mean age: 18.9 years | - | - | 35.92± 32.01 | 0.12 |
WTP for 10% increase in |
|
|
|
|
|
mean age: 20.3 years | 77.3 | - | - | - | - |
|
|
|
|
|
mean age: 23.5 years | 89.7 | 87.75 | 152.48 | 1.34 |
30% affirmed that they could |
|
|
|
|
|
mean age: 43.47years |
Bivalent: 76.9 |
Bivalent: 68.9 |
Bivalent: 24.5 (16.3-32.7 ) |
Bivalent 0.40 | Participants would pay more for quadrivalent vaccine as compared to bivalent vaccine. |
|
|
financial limitations ( |
|
|
Students mean age: 13.1 |
Students:26.1 | - |
Students: | - | - |
|
| - |
|
| median age:37 | 90.1 | 59.8 | 30.28 (0.91-165.8) | 0.23 |
About 12% were willing to vaccinate their |
|
| - |
|
| About 70% has 36--49 years | - | 53.1 |
34.5 ( | 1.47 | 65.6% viewed the cost as Expensive or Very Expensive |
|
|
|
|
|
About 75% has 31--50 years. | 92.5 | 91.6 | 11.6 | 0.43 | most frequently stated amount was US$ 5.02 |
|
|
|
|
| About 53% has more than 40 years. | - | 79.8 | 282.32 | 0.63 | About 25% WTP more than US$344 |
|
|
|
|
| - |
girls: 84.9 | - | 64.5% of participants: 125 | 0.29 | About 8% WTP more than US$125 |
Parents: |
| |
|
| - | - | - | US$1098 to US$1233 (US$913–1004) | 6.06 to 6.81 (5.04-5.54) |
VSL was estimated at approximately US$0.65 to US$4.09 (US$0.56– | - |
|
|
|
|
Mean age:39 | - | - |
reduced the risk of dying of | 0.65 |
No statistically significant differences were seen in the |
|
|
|
|
|
60% has more than 40 years. | 62 | 35.6 | 20.5 ± 8.1 | 1.61 |
62 % Willingness to vaccinate their daughter |
|
|
|
|
|
mean age: 28 | 97 | 76 | - | - | - |
|
|
|
|
|
majority of the respondents were age 31–35 years | 58.5 |
2vHPV (81.2)4vHPV (75.9) 9vHPV (67.7) | - | - | - |
|
|
|
|
| majority of the respondents were age 19-22 | 53.5 | - | - | - | - |
|
|
|
|
|
mean age was 37.09 years | 63.3 | 30 | - | - | Local residents had a relatively higher awareness of HPV and its vaccine, as well as a higher willingness to receive HPV vaccination than non-permanent residents and floating population. |
|
|
|
|
| majority of the respondent (31.5%) had 46 and more age year | - | 67.1 | 3.94±1.64 | 0.1 | - |
|
|
|
|
|
the mean age was 32.86 years | 87.9 | 57.4 | - | - | Only 4.38% of the respondents had previously received CC screening |
|
|
|
|
|
mean age:44 | 76 | 63 | - | - | - |
|
| - |
|
|
About 56% has more than 40 years. |
men | - | - | - |
35.5% of men and 39.1% of |
|
|
|
|
|
66.2% of students were female | - | - | 397.6 | 3.56 |
Students were WTP US$ 450.6vaccinate their |
|
|
|
|
|
mean age was 26.8 | - | 86.6 | 49.3 (44.4—54.3) | 2.27 |
Male WTP is more than Female |
|
|
|
Fig. 2Results of the meta-analysis of the overall acceptance rate, willingness to pay, and percentage of positive willingness to pay based on GDP per capita for cervical cancer prevention methods based on participant variables, countries' economic segregation and types of prevention methods.
| Variable | Variable Level | Dimension Statues (95% CI) | Heterogeneity Test (95% CI) | ||||||
| Percent | Lower limit | Upper limit | df | Q | p | I 2 | |||
| Acceptance rate of CCS | Participants | Girls | 48 | 15 | 142 | 1 | 51.58 | 0.000 | 98.061 |
| Others | 43 | 25 | 73 | 0 | 0.00 | 1.000 | 0.000 | ||
| Parents/Mothers | 63 | 53 | 76 | 9 | 69.7 | 0.000 | 87.1 | ||
| Students | 62 | 44 | 86 | 4 | 24.5 | 0.000 | 83.7 | ||
| Women | 78 | 63 | 96 | 4 | 20.9 | 0.165 | 80.7 | ||
| Country by economies | High-Income Economies (HIEs) | 56 | 40 | 77 | 6 | 119.9 | 0.000 | 94.999 | |
| Lower-Middle Income Economies (LMIEs) | 83 | 64 | 108 | 2 | 3.810 | 0.149 | 47.511 | ||
| Low-Income Economies (LIEs) | 88 | 75 | 103 | 0 | 0 | 1 | 1 | ||
| Upper-Middle-Income Economies (UMIEs) | 63 | 55 | 71 | 11 | 40.4 | 0.000 | 72.8 | ||
| Type of prevention methods | HPV | 60.3 | 53 | 69 | 19 | 175.4 | 0.000 | 89.5 | |
| Pap-smear | 89.3 | 69 | 115 | 0 | 0.00 | 1.000 | 0.000 | ||
| screening service | 89.5 | 77 | 104 | 0 | 0.25 | 0.61 | 0.000 | ||
| Rate of Positive WTP | Participants | Girls | 55 | 46 | 65 | 0 | 0.00 | 1.000 | 0.000 |
| Health Professionals | 85 | 67 | 106 | 1 | 0.016 | 0.900 | 0.000 | ||
| Others | 87 | 65 | 115 | 0 | 0.00 | 1.000 | 0.000 | ||
| Parents/Mothers | 67 | 59 | 74 | 7 | 17 | 0.017 | 58.9 | ||
| Students | 87 | 66 | 113 | 1 | 0.00 | 0.942 | 0.000 | ||
| Women | 58 | 40 | 82 | 7 | 137 | 0.000 | 94.9 | ||
| Country by economies | High-Income Economies (HIEs) | 65 | 56 | 75 | 5 | 22.4 | 0.000 | 77.7 | |
| Lower-Middle Income Economies (LMIEs) | 67 | 53 | 86 | 5 | 15.7 | 0.008 | 68.2 | ||
| Low-Income Economies (LIEs) | 73 | 54 | 96 | 2 | 6 | 0.04 | 66.9 | ||
| Upper-Middle-Income Economies (UMIEs) | 64 | 43 | 96 | 6 | 13.7 | 0.00 | 95.6 | ||
| Type of prevention methods | HPV | 63 | 52 | 76 | 15 | 197.2 | 0.000 | 92.3 | |
| Pap-smear | 89 | 69 | 115 | 0 | 0.0 | 1.000 | 0.000 | ||
| screening service | 71 | 61 | 83 | 4 | 7.1 | 0.1 | 43.7 | ||
|
WTP as a | Participants | Girls | 0.19 | 0 | 0.24 | 1 | 0.1 | 0.733 | 0.000 |
| Health Professionals | 1 | 011 | 9.1 | 1 | 0.0 | 0.937 | 0.000 | ||
| Others | 2.27 | 0.35 | 14.3 | 0 | 0.0 | 1.000 | 0.000 | ||
| Parents/Mothers | 0.40 | 0.10 | 1.51 | 6 | 0.0 | 1.000 | 0.000 | ||
| Students | 1.78 | 0.29 | 10.5 | 3 | 0.5 | 0.904 | 0.000 | ||
| Women | 0.94 | 0.31 | 2.09 | 5 | 1.01 | 0.96 | 0.000 | ||
| Country by economies | High-Income Economies (HIEs) | 0.39 | 0.13 | 1.19 | 8 | 0.7 | 0.999 | 0.000 | |
| Lower-Middle Income Economies (LMIEs) | 1.54 | 0.49 | 4.79 | 4 | 0.91 | 0.91 | 0.000 | ||
| Low-Income Economies (LIEs) | 1 | 0.1 | 9.12 | 1 | 0.0 | 0.937 | 0.000 | ||
| Upper-Middle-Income Economies (UMIEs) | 1 | 0.26 | 4.13 | 5 | 1.4 | 0.923 | 0.000 | ||
| Type of prevention methods | HPV | 0.91 | 0.43 | 1.90 | 16 | 505 | 0999 | 0.000 | |
| Pap-smear | 0.53 | 0.02 | 1.14 | 1 | 0.00 | 0936 | 0.000 | ||
| screening service | 0.63 | 0.12 | 3.3 | 2 | 0.27 | 0.87 | 0.000 | ||
Fig. 3
Fig. 4
Fig. 5The Most Significant and Nonsignificant Effective Factors in Acceptance and Willingness to Pay for Cervical Cancer Prevention Methods
| Variable | Significant positive | Nonsignificant |
|
| ************ | *** |
|
| *********** | *** |
|
| ** | |
|
| ** | ** |
|
| **** | ** |
|
| ***** | ** |
|
| * | |
|
| * | |
|
| ***** | ****** |
|
| ********** | **** |
|
| *** | |
|
| **** | ** |
|
| ** | * |
|
| ***** | *** |
|
| * | |
|
| ** | |
|
| ** | |
|
| *** | |
|
| ** | * |
|
| * | |
|
| * | * |
|
| *** | |
|
| ** | |
|
| *** | *** |
|
| **** | *** |
|
| ** | ** |
|
| * | |
|
| * | |
|
| ** | |
|
| * | |
|
| * |
* Number/ frequency
Example of Quality Assessment of Included Studies
| Question | Wordsworth S, et al: 2001 |
Choi HCW | |
| 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | Yes | Yes |
| 2 | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Yes | Yes |
| 3 | Explain the scientific background and rationale for the investigation being reported | Yes | Yes |
| 4 | State specific objectives, including any prespecified hypotheses | Yes | Yes |
| 5 | Present key elements of study design early in the paper | Yes | Yes |
| 6 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Yes | Yes |
| 7 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | Yes | Yes |
| 8 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Yes | Yes |
| 9 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Yes | Yes |
| 10 | Describe any efforts to address potential sources of bias | No | No |
| 11 | Explain how the study size was arrived at | Yes | Yes |
| 12 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Yes | Yes |
| 13 | (a) Describe all statistical methods, including those used to control for confounding | Yes | Yes |
| 14 | (b) Describe any methods used to examine subgroups and interactions | No | No |
| 15 | (c) Explain how missing data were addressed | No | Yes |
| 16 | (d) If applicable, describe analytical methods taking account of sampling strategy | Yes | Yes |
| 17 | (e) Describe any sensitivity analyses | No | No |
| 18 | (b) Give reasons for non-participation at each stage | No | No |
| 19 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Yes | Yes |
| 20 | (b) Indicate number of participants with missing data for each variable of interest | No | No |
| 21 | Report numbers of outcome events or summary measures | Yes | Yes |
| 22 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Yes | Yes |
| 23 | (b) Report category boundaries when continuous variables were categorized | Yes | Yes |
| 24 | Summarise key results with reference to study objectives | Yes | Yes |
| 25 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Yes | Yes |
| 26 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Yes | Yes |
| 27 | Discuss the generalisability (external validity) of the study results | Yes | Yes |
| 28 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | No | Yes |
| 29 | Does a detailed description of goods or services in question offered to the respondents? | No | Yes |
| 30 | Does the information and attributes expressed in goods or services scenarios is obtained from user or key informant assessments (e.g. focus groups, Delphi panels, interviews etc)? | No | Yes |
| 31 | Was there a pilot study conducted to assess the survey tool/design? | No | No |
| 32 | Does the survey involve face to face interviews? | No | No |
| 33 | Were those involved in data collection adequately trained? | No | NA |
Search Strategy
| Database | Query | Items found |
| Pubmed | Search ((((((("Early Detection of Cancer"[Majr]) OR "Papanicolaou Test"[Majr]) OR "Human Papillomavirus DNA Tests"[Majr]) OR "Vaginal Smears"[Majr]) OR ((((((((((("cancer screening"[Title/Abstract]) OR "follow up testing"[Title/Abstract]) OR "pap smear"[Title/Abstract]) OR "hpv test"[Title/Abstract]) OR "human papillomavirus"[Title/Abstract]) OR "risk reduction"[Title/Abstract]) OR "cancer prevention/cancer risk"[Title/Abstract]) OR "human papilloma virus"[Title/Abstract]) OR "cervical excision"[Title/Abstract]) OR "pap test"[Title/Abstract])))) AND (((("Vaginal Neoplasms"[Majr]) OR "Vulvar Neoplasms"[Majr]) OR "Uterine Cervical Neoplasms"[Majr]) OR (((("cervical cancer"[Title/Abstract]) OR "vaginal cancer"[Title/Abstract]) OR "vulvar cancer"[Title/Abstract]) OR "uterine cervix cancer"[Title/Abstract]))) AND (((((((((((((((((((("willingness to pay"[Title/Abstract]) OR "willing to pay"[Title/Abstract]) OR "willing to accept"[Title/Abstract]) OR WTP[Title/Abstract]) OR "patient preference"[Title/Abstract]) OR "patient acceptance"[Title/Abstract]) OR "stated preference"[Title/Abstract]) OR "revealed preference"[Title/Abstract]) OR "consumers' hypothetical"[Title/Abstract]) OR "willingness to accept"[Title/Abstract]) OR WTA[Title/Abstract]) OR CVM[Title/Abstract]) OR "contingent valuation method"[Title/Abstract]) OR "contingent valuation survey"[Title/Abstract]) OR "cost benefit analysis"[Title/Abstract]) OR "economic evaluation"[Title/Abstract]) | 184 |
| Web of Science |
# 1 | 245 |
| Scopus | (TITLE-ABS-KEY( "Early Detection of Cancer" OR "Papanicolaou Test" OR "Human Papillomavirus DNA Tests" OR "Vaginal Smears" OR "cancer screening" OR "follow up testing" OR "pap sme ar" OR "hpv test" OR "human papillomavirus" OR "risk reduction" OR "cancer prevention/cancer risk" OR "human papilloma virus" OR "cervical excision" OR "pap tests" ))AND(TITLE-ABS-KEY( "Vaginal Neoplasms" OR "Vulvar Neoplasms" OR " Uterine Cervical Neoplasms" OR "cervical cancer" OR "vaginal cancer" OR "vulvar cancer" OR "uterine cervix cancer" ))AND(TITLE-ABS-KEY( "willingness to pay" OR "willing to pay" OR "willing to accept" OR wtp OR "patient preference" OR "patient acceptance" OR "stated preference" OR "revealed preference" OR "consumers' hypothetical" OR "willingness to accept" OR wta OR cvm OR "contingent valuation method" OR "contingent valuation survey" OR "cost benefit analysis" OR "economic evaluation" )) | 2477 |
|
Embase | 'willingness to pay':ti,ab OR 'willing to pay':ti,ab OR 'willing to accept':ti,ab OR wtp:ti,ab OR 'patient preference':ti,ab OR 'patient acceptance':ti,ab OR 'stated preference':ti,ab OR 'revealed preference':t i,ab OR 'consumers hypothetical':ti,ab OR 'willingness to accept':ti,ab OR wta:ti,ab OR cvm:ti,ab OR 'contingent valuation method':ti,ab OR 'contingent valuation survey':ti,ab OR 'cost benefit analysis':ti,ab OR 'economic evaluation':ti,ab | 188 |